IN2004KO01960A - - Google Patents

Info

Publication number
IN2004KO01960A
IN2004KO01960A IN1960KO2004A IN2004KO01960A IN 2004KO01960 A IN2004KO01960 A IN 2004KO01960A IN 1960KO2004 A IN1960KO2004 A IN 1960KO2004A IN 2004KO01960 A IN2004KO01960 A IN 2004KO01960A
Authority
IN
India
Prior art keywords
escherichia coli
helicobacter species
zoonotic helicobacter
zoonotic
oligosaccharide
Prior art date
Application number
Other languages
English (en)
Inventor
Jonas Angstroem
Susann Teneberg
Juhani Saarinen
Tero Satomaa
Niamh Roche
Jari Natunen
Halina Miller-Podraza
Karl-Anders Karlsson
Maan Abul-Milh
Original Assignee
Glykos Finland Oy
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from FI20021275A external-priority patent/FI20021275A0/fi
Priority claimed from FI20030564A external-priority patent/FI20030564A0/fi
Application filed by Glykos Finland Oy filed Critical Glykos Finland Oy
Publication of IN2004KO01960A publication Critical patent/IN2004KO01960A/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56911—Bacteria
    • G01N33/56922—Campylobacter
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/40—Complete food formulations for specific consumer groups or specific purposes, e.g. infant formula
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/702—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56905—Protozoa
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56911—Bacteria
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56911—Bacteria
    • G01N33/56916—Enterobacteria, e.g. shigella, salmonella, klebsiella, serratia
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Food Science & Technology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nutrition Science (AREA)
  • Polymers & Plastics (AREA)
  • Mycology (AREA)
  • Pediatric Medicine (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Obesity (AREA)
IN1960KO2004 2002-06-28 2004-12-20 IN2004KO01960A (cg-RX-API-DMAC7.html)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FI20021275A FI20021275A0 (fi) 2002-06-28 2002-06-28 Terapeuttiset koostumukset käytettäväksi ripulien ehkäisyyn tai hoitoon
FI20030564A FI20030564A0 (fi) 2003-04-14 2003-04-14 Zoonoottisia Helicobacter-lajeja sitovia aineita ja niiden käyttö

Publications (1)

Publication Number Publication Date
IN2004KO01960A true IN2004KO01960A (cg-RX-API-DMAC7.html) 2006-07-21

Family

ID=30001920

Family Applications (1)

Application Number Title Priority Date Filing Date
IN1960KO2004 IN2004KO01960A (cg-RX-API-DMAC7.html) 2002-06-28 2004-12-20

Country Status (10)

Country Link
US (1) US20060014717A1 (cg-RX-API-DMAC7.html)
EP (2) EP2272522B1 (cg-RX-API-DMAC7.html)
JP (1) JP5219329B2 (cg-RX-API-DMAC7.html)
AT (1) ATE428430T1 (cg-RX-API-DMAC7.html)
AU (1) AU2003242799A1 (cg-RX-API-DMAC7.html)
DE (1) DE60327211D1 (cg-RX-API-DMAC7.html)
DK (1) DK1531832T3 (cg-RX-API-DMAC7.html)
ES (1) ES2649736T3 (cg-RX-API-DMAC7.html)
IN (1) IN2004KO01960A (cg-RX-API-DMAC7.html)
WO (1) WO2004002495A1 (cg-RX-API-DMAC7.html)

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002952121A0 (en) * 2002-10-17 2002-10-31 Alchemia Limited Novel carbohydrate based anti-bacterials
RS20050532A (sr) 2003-01-14 2007-12-31 Arena Pharmaceuticals Inc., Derivati 1,2,3-trisupstituisanog arila i heteroarila kao modulatori metabolizma za profilaksu i tretman poremećaja povezanih sa njim, kao što su dijebetes i hiperglikemija
KR20060056944A (ko) 2003-07-14 2006-05-25 아레나 파마슈티칼스, 인크. 대사 조절제로서 융합된 아릴 및 헤테로아릴 유도체 및이에 관련된 장애의 예방 또는 치료
GB0321996D0 (en) * 2003-09-19 2003-10-22 Novartis Nutrition Ag Organic compounds
DE602004021831D1 (de) † 2003-10-13 2009-08-13 Nestec Sa Mässigung der wirkung von endotoxinen
EP1634599A1 (en) 2004-08-20 2006-03-15 N.V. Nutricia Iimmune stimulatory infant nutrition
DK1629850T4 (da) 2004-08-24 2013-07-01 Nutricia Nv Næringssammensætning indeholdende ufordøjelige oligosaccharider
MY148521A (en) 2005-01-10 2013-04-30 Arena Pharm Inc Substituted pyridinyl and pyrimidinyl derivatives as modulators of metabolism and the treatment of disorders related thereto
WO2007090894A1 (en) * 2006-02-10 2007-08-16 Nestec S.A. Oligosaccharide mixture
US20080208486A1 (en) * 2006-03-23 2008-08-28 Jari Natunen Integrated System, Device and Use Thereof
JP5077623B2 (ja) * 2006-03-30 2012-11-21 Ｄｉｃ株式会社 カシュー油変性固形フェノール樹脂の製造方法とゴム組成物
US20080071148A1 (en) * 2006-04-03 2008-03-20 Massachusetts Institute Of Technology Glycomic patterns for the detection of disease
FI20060946A0 (fi) * 2006-10-26 2006-10-26 Glykos Finland Oy Influenssaviruksen nukleiinihappoja ja peptidejä
FI20065800A0 (fi) * 2006-12-13 2006-12-13 Glykos Finland Oy Polyvalentit biokonjugaatit
FI20075030A0 (fi) * 2007-01-18 2007-01-18 Suomen Punainen Risti Veripalv Menetelmä solujen modifioimiseksi
FI20070471A0 (fi) * 2007-06-13 2007-06-13 Glykos Finland Oy Ravinnelisäkompositiota
NZ581390A (en) * 2007-06-25 2012-09-28 Dsm Ip Assets Bv Prebiotics comprising an oligosaccharide, sialyloligosaccharide and free sialic acid
MX2010002562A (es) * 2007-09-07 2011-04-11 Inst Nac De Ciencias Medicas Y Nutricion Uso de los niveles de antigeno secretor, de lewis y de sialilo como predictores para enfermedad.
ES2748136T3 (es) 2007-10-15 2020-03-13 United Animal Health Inc Método para aumentar el rendimiento de las crías
MY159076A (en) * 2007-11-08 2016-12-15 Nestec Sa Use of oligosaccharides containing n-acetyllactosamine for maturation of immune responses in neonates
EP2265135B1 (en) * 2008-03-14 2017-12-20 Nestec S.A. Synbiotic mixture
EP2143341A1 (en) 2008-07-08 2010-01-13 Nestec S.A. Nutritional Composition Containing Oligosaccharide Mixture
US8586029B2 (en) * 2008-06-04 2013-11-19 Trustees Of Dartmouth College Prevention or treatment of immune-relevant disease by modification of microfloral populations
GB0817908D0 (en) * 2008-10-01 2008-11-05 Univ Ghent Blood group a/b/h determinant on type 1 core glycosphinglipids chain as recognition point for the fedf protein of f18-fimbriated enterotoxigenic
JP5383692B2 (ja) * 2008-10-10 2014-01-08 公益財団法人野口研究所 ピロリ菌増殖抑制剤
FI20080665A0 (fi) 2008-12-18 2008-12-18 Glykos Finland Oy Luonnollisen tyyppiset sakkaridikoostumukset
US20100311686A1 (en) * 2009-06-03 2010-12-09 Kasper Lloyd H Nutraceutical composition and methods for preventing or treating multiple sclerosis
US8580278B2 (en) 2009-06-03 2013-11-12 Trustees Of Dartmouth College Nutraceutical composition and methods for preventing or treating multiple sclerosis
FI20105824A0 (fi) * 2010-07-26 2010-07-26 Suomen Punainen Risti Veripalv Veriryhmästatuksen käyttö IV
CN103221410B (zh) 2010-09-22 2017-09-15 艾尼纳制药公司 Gpr119受体调节剂和对与其相关的障碍的治疗
DK2658399T4 (da) * 2010-12-31 2024-03-25 Abbott Lab Ernæringssammensætninger omfattende humane mælkeoligosaccharider til anvendelse i behandling og/eller forebyggelse af enterisk rotavirus-infektion
US8795746B2 (en) 2011-02-16 2014-08-05 The Board Of Trustees Of The Leland Stanford Junior University Therapeutic use of mucin glycans
JP6129821B2 (ja) 2011-05-13 2017-05-17 グリコシン リミテッド ライアビリティー カンパニー プレバイオティクスとしての、精製された２’−フコシルラクトース、３−フコシルラクトース、およびラクトジフコテトラオースの使用
US9539281B2 (en) 2011-07-12 2017-01-10 The Brigham And Women's Hospital, Inc. Lipid-containing PSA compositions, methods of isolation and methods of use thereof
EP2844301A2 (en) * 2012-05-04 2015-03-11 Ineb-instituto de Engenharia Biomédica Microspheres for treating helicobacter pylori infections
US10626460B2 (en) 2013-02-21 2020-04-21 Children's Hospital Medical Center Use of glycans and glycosyltransferases for diagnosing/monitoring inflammatory bowel disease
EP2857410A1 (en) * 2013-10-04 2015-04-08 Jennewein Biotechnologie GmbH Process for purification of 2´-fucosyllactose using simulated moving bed chromatography
CN103622901B (zh) * 2013-11-21 2016-01-20 广州立白企业集团有限公司 一种能调节皮肤微生态平衡的皮肤清洁剂组合物及其制备方法
JP7158096B2 (ja) 2014-07-09 2022-10-21 カデナ バイオ，インコーポレーテッド オリゴ糖組成物及びその生成方法
AR104469A1 (es) * 2014-08-08 2017-07-26 Glycovaxyn Ag Células huésped modificadas para su uso en producción de bioconjugados
CA3002540C (en) 2015-01-06 2023-11-07 Arena Pharmaceuticals, Inc. Use of (r)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid for treating conditions related to the s1p1 receptor
EP3862002A1 (en) * 2015-01-26 2021-08-11 Kaleido Biosciences, Inc. Glycan therapeutics and related methods thereof
ES2755042T3 (es) 2015-01-26 2020-04-21 Cadena Bio Inc Composiciones de oligosacáridos para el uso como alimento para animales y sus métodos para producirlas
MX378680B (es) 2015-03-05 2025-03-11 Soc Des Produits Nestle S A Star Composiciones para usar en la prevencion o el tratamiento de infecciones/inflamaciones gastrointestinales en infantes o niños pequeños.
PT3264922T (pt) 2015-03-05 2025-01-07 Nestle Sa Composições para utilização na melhoria da consistência ou frequência das fezes em lactentes ou crianças pequenas
EP3285777B1 (en) 2015-04-23 2021-06-09 Kaleido Biosciences, Inc. Glycan therapeutics and methods of treatment
US10857167B2 (en) 2015-04-28 2020-12-08 Children's Hospital Medical Center Use of oligosaccharide compositions to enhance weight gain
JP6838744B2 (ja) 2015-06-22 2021-03-03 アリーナ ファーマシューティカルズ， インコーポレイテッド Ｓ１Ｐ１レセプター関連障害における使用のための（Ｒ）−２−（７−（４−シクロペンチル−３−（トリフルオロメチル）ベンジルオキシ）−１，２，３，４−テトラヒドロシクロペンタ［ｂ］インドール−３−イル）酢酸（化合物１）の結晶性Ｌ−アルギニン塩
CN108135167B (zh) 2015-08-19 2021-07-09 哈佛学院院长及董事 脂化psa组合物和方法
CN105410913B (zh) * 2015-12-01 2018-06-01 辽宁三合酒业有限公司 一种壳寡糖口腔清洁含片的制备方法
WO2018014012A1 (en) 2016-07-15 2018-01-18 President And Fellows Of Harvard College Glycolipid compositions and methods of use
MX2018015187A (es) 2016-08-04 2019-04-24 Nestec Sa Composiciones nutricionales con 2fl y lnnt para su uso en la prevencion y/o tratamiento de la diarrea no causada por rotavirus mediante la accion en la disbiosis de la microbiota intestinal.
CN110520124A (zh) 2017-02-16 2019-11-29 艾尼纳制药公司 用于治疗原发性胆汁性胆管炎的化合物和方法
US12090168B2 (en) 2017-11-03 2024-09-17 Dsm Nutritional Products, Llc Glucose glycans for treating urea cycle disorders
CN108018805B (zh) * 2017-12-31 2018-12-04 江苏来德福汽车部件有限公司 一种太阳能的智能移动护栏
JP7397011B2 (ja) 2018-06-06 2023-12-12 アリーナ ファーマシューティカルズ， インコーポレイテッド Ｓ１ｐ１受容体に関連する状態を治療する方法
EP3833195A1 (en) * 2018-08-08 2021-06-16 Mars Incorporated Pet food products comprising oligosaccharides and methods of use
CN109212227B (zh) * 2018-09-07 2021-07-16 深圳格道糖生物技术有限公司 基于唾液特异糖蛋白糖链结构的肝病/肝硬化相关筛查、评估的产品及应用
WO2025083289A1 (en) 2023-10-19 2025-04-24 N.V. Nutricia Mixture of human milk oligosaccharides
CN122341284A (zh) 2023-10-19 2026-07-03 纽迪希亚公司 人乳寡糖混合物

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5225330A (en) * 1988-08-01 1993-07-06 The United States Of America As Represented By The Department Of Health And Human Services Diagnostic kit and diagnostic method utilizing carbohydrate receptors
US5217715A (en) * 1988-08-01 1993-06-08 The United States Of America As Represented By The Department Of Health And Human Services Carbohydrate receptor for bacteria and method for use thereof
MX9304638A (es) * 1992-07-31 1994-05-31 Neose Pharm Inc Composicion para tratar e inhibir las ulceras gastricas y duodenales.
WO1996002255A1 (en) * 1994-07-15 1996-02-01 Taiyo Kagaku Co., Ltd. Medicinal composition containing sialic acid derivative
US5627163A (en) * 1995-06-05 1997-05-06 Synsorb Biotech, Inc. Treatment of traveller's diarrhea
US6045854A (en) * 1997-03-31 2000-04-04 Abbott Laboraties Nutritional formulations containing oligosaccharides
NL1010770C2 (nl) * 1998-12-09 2000-06-13 Nutricia Nv Preparaat dat oligosacchariden en probiotica bevat.
US6291435B1 (en) * 1999-03-04 2001-09-18 The Governs Of The University Of Alberta Treatment of diarrhea caused by enteropathogenic Escherichia coli
SE9904581D0 (sv) * 1999-12-15 1999-12-15 A & Science Invest Ab A novel helicobacter pylori-binding substance and use thereof
FI20010118L (fi) * 2001-01-19 2002-07-20 Carbion Oy Uudet helicobacter pylori reseptorit ja niiden käyttö
EP1411952B1 (en) * 2001-06-29 2009-04-22 Glykos Finland Oy Use of at least one glycoinhibitor substance against infectious diseases

Also Published As

Publication number Publication date
ATE428430T1 (de) 2009-05-15
WO2004002495A1 (en) 2004-01-08
JP5219329B2 (ja) 2013-06-26
AU2003242799A1 (en) 2004-01-19
ES2649736T3 (es) 2018-01-15
EP2272522B1 (en) 2017-09-06
EP2272522A2 (en) 2011-01-12
US20060014717A1 (en) 2006-01-19
DK1531832T3 (da) 2009-07-27
EP1531832A1 (en) 2005-05-25
DE60327211D1 (de) 2009-05-28
JP2006506329A (ja) 2006-02-23
EP1531832B1 (en) 2009-04-15
EP2272522A3 (en) 2011-04-20

Similar Documents

Publication Publication Date Title
AU2003242799A1 (en) Therapeutic compositions for use in prophylaxis or treatment of diarrheas
GEP20074197B (en) 5ht2c receptor modulators
IL145830A0 (en) Pharmaceutical compositions containing a compound which activates a receptor for glucagon-like peptide-1
AU2003217055A1 (en) Protein for use in hypoxia related conditions
GT200200188A (es) Preparacion y uso de derivados de imidazol para el tratamiento de la obesidad
MX9203050A (es) Compuestos de analogos de triptamina.
TNSN07093A1 (en) Bicyclic amides as kinase inhibitors
DE60224172D1 (de) Formanilid-derivative als beta2-adrenorezeptor-agonisten
DE60220887D1 (de) Agonisten von beta-adrenorezeptoren
WO2004024068A3 (en) Novel composition and methods for the treatment of immune related diseases
FI20011403A7 (fi) Menetelmä ja koostumukset vatsan sairauksien hoitoon
MY145077A (en) Pyrrolotriazine derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis
DE60313004D1 (de) Alpha-7-nikotinsäure-rezeptoragonisten und statine in kombination
PL2018169T3 (pl) Zastosowanie 4,17β-dihydroksyandrost-4-en-3-onu do leczenia raków
IL197642A (en) Heterocyclic Derivatives and Their Uses to Prepare Pharmaceutical Preparations for the Treatment of Opioid Receptor Syndromes
DK0583421T3 (da) Substituerede dibenzoxazepinforbindelser, lægemidler og fremgangsmåder til anvendelse
DK1551803T3 (da) Azabicycloderivater som muskarine receptorantagonister
RU2004127960A (ru) Применение композиций витамина d
MY141528A (en) Anilinopyrazole derivatives useful for the treatment of diabetes
ES2194677T3 (es) Suspensiones de trovafloxacina de administracion por via oral.
MXPA03003264A (es) Tratamiento de trastornos afectivos mediante la accion combinada de un agonista del receptor nicotinico y una sustancia monoaminergica.
EE05182B1 (et) Asendatud homopiperidlbensimidasooli analoog, meetod selle valmistamiseks ning seda sisaldav farmatseutiline kompositsioon
IL165220A0 (en) Novel compounds, their use and preparation
BR0212249A (pt) Composto, composição farmacêutica, método de tratamento ou profilaxia de doenças, e, uso de um composto
BR0213696A (pt) Agonistas do receptor de acetilcolina nicotìnicos no tratamento da sìndrome de pernas inquietas